泰恩康(301263.SZ)：控股子公司CKBA乳膏申报儿童白癜风临床试验取得受理通知书
T&KT&K(SZ:301263) Ge Long Hui A P P·2025-11-20 08:15

Core Viewpoint - The company, Taiankang (301263.SZ), has received a notice from the National Medical Products Administration, indicating the acceptance of its application for a Phase II clinical study of CKBA cream for treating non-segmental vitiligo in children aged 2 to 12 years [1] Group 1 - The application pertains to a multi-center, randomized, double-blind, placebo-controlled clinical study [1] - The study will evaluate the safety, tolerability, efficacy, and pharmacokinetic characteristics of CKBA cream in the specified age group [1]